View Older Stories View More Recent Stories

Feb 8, 2016 01:00AM Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination Plan.
Feb 3, 2016 01:00AM Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs
Jan 20, 2016 01:00AM Celyad Announces 2016 Financial Calendar
Jan 20, 2016 01:00AM Celyad Announces 2016 Financial Calendar
Jan 5, 2016 01:00AM Celyad Completes 30-Day Safety Follow-up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
Jan 5, 2016 01:00AM Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
Dec 23, 2015 01:00AM Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference
Dec 23, 2015 01:00AM Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference
Dec 21, 2015 01:00AM Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND
Dec 21, 2015 01:00AM Celyad Receives Clearance from the US FDA on Its CHART-2 Phase III IND
Dec 16, 2015 07:00AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Dec 16, 2015 01:00AM Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure
Dec 16, 2015 01:00AM Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure
Dec 1, 2015 01:00AM Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
Dec 1, 2015 01:00AM Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial
Nov 19, 2015 01:00AM Celyad Announces Third Quarter 2015 Business Update
Nov 19, 2015 01:00AM Celyad Announces Third Quarter 2015 Business Update
Nov 19, 2015 01:00AM Celyad Announces Third Quarter 2015 Business Update
Nov 10, 2015 01:00AM Celyad Successfully Completes 30-Day Safety Follow-up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial
Nov 10, 2015 01:00AM Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial
Nov 10, 2015 01:00AM Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial
Nov 6, 2015 01:00AM Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts
Nov 6, 2015 01:00AM Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts
Oct 23, 2015 01:00AM First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells ("CAR-T") Modified to Reduce Immunogenicity is Awarded to Celyad
Oct 23, 2015 01:00AM First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells ("CAR-T") Modified to Reduce Immunogenicity is Awarded to Celyad
Oct 23, 2015 01:00AM First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad
Sep 15, 2015 01:00AM Celyad Announces the Appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology
Sep 15, 2015 01:00AM Celyad Announces the Appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology
Sep 15, 2015 01:00AM Celyad Announces the Appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology
Sep 4, 2015 01:00AM Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director
Sep 4, 2015 01:00AM Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director
Sep 4, 2015 01:00AM Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director
Aug 31, 2015 01:00AM Celyad Announces Commercial License Agreement for C-Cure® in Greater China
Aug 31, 2015 01:00AM Celyad Announces Commercial License Agreement for C-Cure(R) in Greater China
Aug 31, 2015 01:00AM Celyad Announces Commercial License Agreement for C-Cure(R) in Greater China
Aug 25, 2015 01:00AM Celyad Reports First Half 2015 Financial Results and Operational Progress
Aug 25, 2015 01:00AM Celyad Reports First Half 2015 Financial Results and Operational Progress
Aug 25, 2015 01:00AM Celyad Reports First Half 2015 Financial Results and Operational Progress
Aug 12, 2015 01:30AM Celyad Announces Details of Upcoming Half Year 2015 Financial Results
Aug 12, 2015 01:30AM Celyad Announces Details of Upcoming Half Year 2015 Financial Results
Aug 12, 2015 01:30AM Celyad Announces Details of Upcoming Half Year 2015 Financial Results
Aug 3, 2015 01:00AM Celyad Completes Final Patient Infusion in CHART-1 Phase III Trial
Aug 3, 2015 01:00AM Celyad Completes Final Patient Infusion in CHART-1 Phase III Trial
Aug 3, 2015 01:00AM Celyad Completes Final Patient Infusion in CHART-1 Phase III Trial
Jun 25, 2015 04:15AM Citi Appointed Depositary Bank for Celyad’s ADR Programme
Jun 24, 2015 10:00AM Celyad Announces Closing of Its Global Offering
Jun 24, 2015 10:00AM Celyad Announces Closing of Its Global Offering
Jun 18, 2015 07:45PM Celyad raises $100.1 million gross proceeds with NASDAQ IPO
Jun 18, 2015 07:10PM Celyad Raises $100.1 Million Gross Proceeds With NASDAQ IPO
Jun 18, 2015 07:10PM Celyad Raises $100.1 Million Gross Proceeds With NASDAQ IPO
View More Recent Stories View Older Stories